Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature

Mutation Research - Reviews in Mutation Research

Volumn 681, Issue 2-3, 2009, Pages 299-307

  Landi, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Genetic susceptibility; Pancreatic cancer; Risk factors

Indexed keywords

BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53;

ALCOHOL ABUSE; BREAST CANCER; CANCER RISK; CARCINOGENESIS; COFFEE; CYSTIC FIBROSIS; DIABETES MELLITUS; DYSKERATOSIS CONGENITA; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPIDERMOLYTIC PALMOPLANTAR KERATODERMA; EXOCRINE GLAND; FAMILIAL ADENOMATOUS POLYPOSIS; FAMILIAL ATYPICAL MOLE MULTIPLE MELANOMA; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; FAMILIAL CANCER; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; MELANOMA PANCREATIC CANCER SYNDROME; MISMATCH REPAIR; MULTIPLE ENDOCRINE NEOPLASIA; MUTATION; NUTRITION; OVARY CANCER; PANCREAS; PANCREAS CANCER; PANCREAS ISLET; PANCREATITIS; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; REVIEW; SMOKING; SYNDROME; VON HIPPEL LINDAU DISEASE;

ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PANCREATIC NEOPLASMS; RISK FACTORS;

EID: 59349089036     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrrev.2008.12.001     Document Type: Review

References (70)

1. Garcea G., Dennison A.R., Pattenden C.J., Neal C.P., Sutton C.D., and Berry D.P. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 9 (2008) 99-132
2. Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., Pukkala E., Skytthe A., and Hemminki K. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343 (2000) 78-85
3. Lilley M., and Gilchrist D. The hereditary spectrum of pancreatic cancer: the Edmonton experience. Can. J. Gastroenterol. 18 (2004) 17-21
4. Klein A.P., Brune K.A., Petersen G.M., Goggins M., Tersmette A.C., Offerhaus G.J., Griffin C., Cameron J.L., Yeo C.J., Kern S., and Hruban R.H. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 64 (2004) 2634-2638
5. McWilliams R.R., Rabe K.G., Olswold C., de A.M., and Petersen G.M. Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer 104 (2005) 388-394
6. Brentnall T.A., Bronner M.P., Byrd D.R., Haggitt R.C., and Kimmey M.B. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann. Intern. Med. 131 (1999) 247-255
7. Meckler K.A., Brentnall T.A., Haggitt R.C., Crispin D., Byrd D.R., Kimmey M.B., and Bronner M.P. Familial fibrocystic pancreatic atrophy with endocrine cell hyperplasia and pancreatic carcinoma. Am. J. Surg. Pathol. 25 (2001) 1047-1053
8. Zogopoulos G., Rothenmund H., Eppel A., Ash C., Akbari M.R., Hedley D., Narod S.A., and Gallinger S. The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Hum. Genet. 121 (2007) 635-637
9. Whelan A.J., Bartsch D., and Goodfellow P.J. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N. Engl. J. Med. 333 (1995) 975-977
10. Goldstein A.M., Fraser M.C., Struewing J.P., Hussussian C.J., Ranade K., Zametkin D.P., Fontaine L.S., Organic S.M., Dracopoli N.C., and Clark Jr. W.H. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N. Engl. J. Med. 333 (1995) 970-974
11. Schutte M., Hruban R.H., Geradts J., Maynard R., Hilgers W., Rabindran S.K., Moskaluk C.A., Hahn S.A., Schwarte-Waldhoff I., Schmiegel W., Baylin S.B., Kern S.E., and Herman J.G. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57 (1997) 3126-3130
12. Lynch H.T., Brand R.E., Hogg D., Deters C.A., Fusaro R.M., Lynch J.F., Liu L., Knezetic J., Lassam N.J., Goggins M., and Kern S. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 94 (2002) 84-96
13. Vasen H.F., Gruis N.A., Frants R.R., van D., Hille V.E.T., and Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int. J. Cancer 87 (2000) 809-811
14. Goldstein A.M., Struewing J.P., Fraser M.C., Smith M.W., and Tucker M.A. Prospective risk of cancer in CDKN2A germline mutation carriers. J. Med. Genet. 41 (2004) 421-424
15. Foulkes W.D., Flanders T.Y., Pollock P.M., and Hayward N.K. The CDKN2A (p16) gene and human cancer. Mol. Med. 3 (1997) 5-20
16. Lim W., Olschwang S., Keller J.J., Westerman A.M., Menko F.H., Boardman L.A., Scott R.J., Trimbath J., Giardiello F.M., Gruber S.B., Gille J.J., Offerhaus G.J., de Rooij F.W., Wilson J.H., Spigelman A.D., Phillips R.K., and Houlston R.S. Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 126 (2004) 1788-1794
17. Yoo J.H., Yoo J.H., Choi Y.J., Kang J.G., Sun Y.K., Ki C.S., Lee K.A., and Choi J.R. A novel de novo mutation in the serine-threonine kinase STK11 gene in a Korean patient with Peutz-Jeghers syndrome. BMC Med. Genet. 9 (2008) 44
18. Sharer N., Schwarz M., Malone G., Howarth A., Painter J., Super M., and Braganza J. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N. Engl. J. Med. 339 (1998) 645-652
19. Finch M.D., Howes N., Ellis I., Mountford R., Sutton R., Raraty M., and Neoptolemos J.P. Hereditary pancreatitis and familial pancreatic cancer. Digestion 58 (1997) 564-569
20. Witt H., Luck W., Hennies H.C., Classen M., Kage A., Lass U., Landt O., and Becker M. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat. Genet. 25 (2000) 213-216
21. Keim V. Role of genetic disorders in acute recurrent pancreatitis. World J. Gastroenterol. 14 (2008) 1011-1015
22. Rebours V., Boutron-Ruault M.C., Schnee M., Ferec C., Maire F., Hammel P., Ruszniewski P., and Levy P. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am. J. Gastroenterol. 103 (2008) 111-119
23. Zhao T., Guo J., Li H., Huang W., Xian X., Ross C.J., Hayden M.R., Wen Z., and Liu G. Hemorheological abnormalities in lipoprotein lipase deficient mice with severe hypertriglyceridemia. Biochem. Biophys. Res. Commun. 341 (2006) 1066-1071
24. Neglia J.P., FitzSimmons S.C., Maisonneuve P., Schoni M.H., Schoni-Affolter F., Corey M., and Lowenfels A.B. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N. Engl. J. Med. 332 (1995) 494-499
25. McWilliams R., Highsmith W.E., Rabe K.G., de A.M., Tordsen L.A., Holtegaard L.M., and Petersen G.M. Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma. Gut 54 (2005) 1661-1662
26. Malats N., Casals T., Porta M., Guarner L., Estivill X., and Real F.X. Cystic fibrosis transmembrane regulator (CFTR) DeltaF508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreatic cancer. PANKRAS II Study Group. Gut 48 (2001) 70-74
27. Cohn J.A., Friedman K.J., Noone P.G., Knowles M.R., Silverman L.M., and Jowell P.S. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N. Engl. J. Med. 339 (1998) 653-658
28. Hsieh P., and Yamane K. DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech. Ageing Dev. 129 (2008) 391-407
29. Tomaszewska R., Okon K., and Stachura J. Expression of the DNA mismatch repair proteins (hMLH1 and hMSH2) in infiltrating pancreatic cancer and its relation to some phenotypic features. Pol. J. Pathol. 54 (2003) 31-37
30. Okada T., Noji S., Goto Y., Iwata T., Fujita T., Okada T., Matsuzaki Y., Kuwana M., Hirakata M., Horii A., Matsuno S., Sunamura M., and Kawakami Y. Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis. Int. J. Cancer 116 (2005) 925-933
31. Geary J., Sasieni P., Houlston R., Izatt L., Eeles R., Payne S.J., Fisher S., and Hodgson S.V. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam. Cancer 7 (2008) 163-172
32. Nakata B., Wang Y.Q., Yashiro M., Nishioka N., Tanaka H., Ohira M., Ishikawa T., Nishino H., and Hirakawa K. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin. Cancer Res. 8 (2002) 2536-2540
33. Johannsson O., Ostermeyer E.A., Hakansson S., Friedman L.S., Johansson U., Sellberg G., Brondum-Nielsen K., Sele V., Olsson H., King M.C., and Borg A. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am. J. Hum. Genet. 58 (1996) 441-450
34. Simard J., Tonin P., Durocher F., Morgan K., Rommens J., Gingras S., Samson C., Leblanc J.F., Belanger C., and Dion F. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat. Genet. 8 (1994) 392-398
35. Risch H.A., McLaughlin J.R., Cole D.E., Rosen B., Bradley L., Kwan E., Jack E., Vesprini D.J., Kuperstein G., Abrahamson J.L., Fan I., Wong B., and Narod S.A. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 68 (2001) 700-710
36. Risch H.A., McLaughlin J.R., Cole D.E., Rosen B., Bradley L., Fan I., Tang J., Li S., Zhang S., Shaw P.A., and Narod S.A. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl. Cancer Inst. 98 (2006) 1694-1706
37. Thorlacius S., Olafsdottir G., Tryggvadottir L., Neuhausen S., Jonasson J.G., Tavtigian S.V., Tulinius H., Ogmundsdottir H.M., and Eyfjord J.E. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat. Genet. 13 (1996) 117-119
38. Ozcelik H., Schmocker B., Di N.N., Shi X.H., Langer B., Moore M., Taylor B.R., Narod S.A., Darlington G., Andrulis I.L., Gallinger S., and Redston M. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat. Genet. 16 (1997) 17-18
39. Schubert E.L., Lee M.K., Mefford H.C., Argonza R.H., Morrow J.E., Hull J., Dann J.L., and King M.C. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am. J. Hum. Genet. 60 (1997) 1031-1040
40. van Asperen C.J., Brohet R.M., Meijers-Heijboer E.J., Hoogerbrugge N., Verhoef S., Vasen H.F., Ausems M.G., Menko F.H., Gomez Garcia E.B., Klijn J.G., Hogervorst F.B., van Houwelingen J.C., van't Veer L.J., Rookus M.A., and van Leeuwen F.E. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J. Med. Genet. 42 (2005) 711-719
41. Goggins M., Schutte M., Lu J., Moskaluk C.A., Weinstein C.L., Petersen G.M., Yeo C.J., Jackson C.E., Lynch H.T., Hruban R.H., and Kern S.E. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 56 (1996) 5360-5364
42. Goggins M., Hruban R.H., and Kern S.E. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am. J. Pathol. 156 (2000) 1767-1771
43. Tavtigian S.V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., Merajver S., Thorlacius S., Offit K., Stoppa-Lyonnet D., Belanger C., Bell R., Berry S., Bogden R., Chen Q., Davis T., Dumont M., Frye C., Hattier T., Jammulapati S., Janecki T., Jiang P., Kehrer R., Leblanc J.F., Mitchell J.T., rthur-Morrison J., Nguyen K., Peng Y., Samson C., Schroeder M., Snyder S.C., Steele L., Stringfellow M., Stroup C., Swedlund B., Swense J., Teng D., Thomas A., Tran T., Tranchant M., Weaver-Feldhaus J., Wong A.K., Shizuya H., Eyfjord J.E., Cannon-Albright L., Tranchant M., Labrie F., Skolnick M.H., Weber B., Kamb A., and Goldgar D.E. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet. 12 (1996) 333-337
44. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 (2002) 171-182
45. Varley J.M. Germline TP53 mutations and Li-Fraumeni syndrome. Hum. Mutat. 21 (2003) 313-320
46. Kleihues P., Schauble B., zur H.A., Esteve J., and Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am. J. Pathol. 150 (1997) 1-13
47. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
48. Vousden K.H., and Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8 (2007) 275-283
49. Karim R., Tse G., Putti T., Scolyer R., and Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology 36 (2004) 120-128
50. Abraham S.C., Wu T.T., Klimstra D.S., Finn L.S., Lee J.H., Yeo C.J., Cameron J.L., and Hruban R.H. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am. J. Pathol. 159 (2001) 1619-1627
51. Giardiello F.M., Offerhaus G.J., Lee D.H., Krush A.J., Tersmette A.C., Booker S.V., Kelley N.C., and Hamilton S.R. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 34 (1993) 1394-1396
52. Thakker R.V. Multiple endocrine neoplasia-syndromes of the twentieth century. J. Clin. Endocrinol. Metab. 83 (1998) 2617-2620
53. Skogseid B., Rastad J., and Oberg K. Multiple endocrine neoplasia type 1. Clinical features and screening. Endocrinol. Metab. Clin. North Am. 23 (1994) 1-18
54. Agarwal S.K., Guru S.C., Heppner C., Erdos M.R., Collins R.M., Park S.Y., Saggar S., Chandrasekharappa S.C., Collins F.S., Spiegel A.M., Marx S.J., and Burns A.L. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96 (1999) 143-152
55. Busygina V., Suphapeetiporn K., Marek L.R., Stowers R.S., Xu T., and Bale A.E. Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. Hum. Mol. Genet. 13 (2004) 2399-2408
56. Fill W.L., Lamiell J.M., and Polk N.O. The radiographic manifestations of von Hippel-Lindau disease. Radiology 133 (1979) 289-295
57. Taouli B., Ghouadni M., Correas J.M., Hammel P., Couvelard A., Richard S., and Vilgrain V. Spectrum of abdominal imaging findings in von Hippel-Lindau disease. AJR Am. J. Roentgenol. 181 (2003) 1049-1054
58. Duan D.R., Pause A., Burgess W.H., Aso T., Chen D.Y., Garrett K.P., Conaway R.C., Conaway J.W., Linehan W.M., and Klausner R.D. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269 (1995) 1402-1406
59. Roe J.S., Kim H., Lee S.M., Kim S.T., Cho E.J., and Youn H.D. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol. Cell 22 (2006) 395-405
60. Yang H., Minamishima Y.A., Yan Q., Schlisio S., Ebert B.L., Zhang X., Zhang L., Kim W.Y., Olumi A.F., and Kaelin Jr. W.G. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol. Cell 28 (2007) 15-27
61. Connor J.M., and Teague R.H. Dyskeratosis congenita. Report of a large kindred. Br. J. Dermatol. 105 (1981) 321-325
62. Stevens H.P., Kelsell D.P., Leigh I.M., Ostlere L.S., MacDermot K.D., and Rustin M.H. Punctate palmoplantar keratoderma and malignancy in a four-generation family. Br. J. Dermatol. 134 (1996) 720-726
63. Everhart J., and Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273 (1995) 1605-1609
64. Ekoe J.M., Ghadirian P., Simard A., Baillargeon J., and Perret C. Diabetes mellitus and pancreatic cancer: a case-control study in greater Montreal, Quebec, Canada. Rev. Epidemiol. Sante Publique 40 (1992) 447-453
65. Wideroff L., Gridley G., Mellemkjaer L., Chow W.H., Linet M., Keehn S., Borch-Johnsen K., and Olsen J.H. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J. Natl. Cancer Inst. 89 (1997) 1360-1365
66. Gapstur S.M., Gann P.H., Lowe W., Liu K., Colangelo L., and Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 283 (2000) 2552-2558
67. Bansal P., and Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 109 (1995) 247-251
68. Lowenfels A.B., Maisonneuve P., Cavallini G., Ammann R.W., Lankisch P.G., Andersen J.R., Dimagno E.P., ndren-Sandberg A., and Domellof L. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N. Engl. J. Med. 328 (1993) 1433-1437
69. Ghadirian P., Lynch H.T., and Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect. Prev. 27 (2003) 87-93
70. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., and Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008) 1801-1806